Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Phenytoin prophylaxis in severe pre-eclampsia and eclampsia

S C Robson1, N Redfern, J Seviour

  • 1RPMS Institute of Obstetrics & Gynaecology, Queen Charlotte's and Chelsea Hospital, London.

British Journal of Obstetrics and Gynaecology
|July 1, 1993
PubMed
Summary

A higher loading dose of phenytoin (17.5 mg/kg) in pre-eclampsia resulted in higher initial plasma levels but also more subtherapeutic levels later. Seizures can still occur even with therapeutic phenytoin levels.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Views of BRCA gene mutation carriers on preimplantation genetic diagnosis as a reproductive option for hereditary breast and ovarian cancer.

Human reproduction (Oxford, England)·2007
Same author

Practical issues drawn from the implementation of the integrated test for Down syndrome screening into routine clinical practice.

BJOG : an international journal of obstetrics and gynaecology·2007
Same author

Uterine vein and maternal urinary levels of activin A and inhibin A in pre-eclampsia patients.

Clinical endocrinology·2006
Same author

Follow-up of uteroplacental vascularization after feticide in third-trimester therapeutic termination of pregnancy with complete placenta previa.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2006
Same author

Thromboembolic disease and air travel in pregnancy: a survey of advice given by obstetricians.

Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology·2005
Same author

Gene therapy progress and prospects: fetal gene therapy--first proofs of concept--some adverse effects.

Gene therapy·2005

Area of Science:

  • Obstetrics and Gynecology
  • Pharmacology
  • Neurology

Background:

  • Severe pre-eclampsia and eclampsia are serious conditions requiring effective seizure prophylaxis.
  • Phenytoin is a commonly used anticonvulsant, but optimal dosing in pregnancy remains a focus of research.

Purpose of the Study:

  • To compare plasma phenytoin levels and seizure outcomes in women with severe pre-eclampsia and eclampsia receiving different intravenous loading doses of phenytoin.
  • To evaluate the efficacy and safety of two phenytoin loading regimens for seizure prophylaxis in pregnant women.

Main Methods:

  • A prospective observational study was conducted in two UK teaching hospitals.
  • Sixty-seven women with severe pre-eclampsia and five with eclampsia were included.
  • Two phenytoin loading regimens were compared: 15 mg/kg (n=29) versus 17.5 mg/kg (n=43), followed by a standardized maintenance dose.

Related Experiment Videos

Main Results:

  • The 17.5 mg/kg loading dose resulted in higher mean plasma phenytoin levels at 30 minutes and 6 hours post-dose.
  • A higher proportion of women in the 17.5 mg/kg group had levels above the therapeutic range at 30 minutes (68% vs 31%).
  • Conversely, the 15 mg/kg group had a higher incidence of subtherapeutic levels at 12 hours (22% vs 5%). Three women experienced seizures despite therapeutic phenytoin levels.

Conclusions:

  • The 15 mg/kg loading dose of phenytoin was associated with fewer initial high plasma levels but more subtherapeutic levels at 12 hours compared to 17.5 mg/kg.
  • Seizures occurred in a small percentage of patients (2-3%) even when plasma phenytoin levels were within the therapeutic range.
  • These findings suggest a need for careful therapeutic drug monitoring of phenytoin in pregnant women with severe pre-eclampsia and eclampsia.